Moleculin Biotech, Inc. (MBRX) stock
MBRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$7.87−0.19 (-2.36%)
Close on Nov 13, 2026Market cap $8.23MP/E –Yield –
Moleculin Biotech cash
Cash and short-term investments held at the end of each period.
Moleculin Biotech's cash was $7.29M at Sep 30, 2026. For fiscal 2025 it was $8.88M, up 107.5% from the year before. Over ten years it grew 77.9% a year on average. The highest annual figure on record is $70.90M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.88M | +107.5% |
| FY2024 | Dec 31, 2024 | $4.28M | -81.8% |
| FY2023 | Dec 31, 2023 | $23.55M | -45.4% |
| FY2022 | Dec 31, 2022 | $43.15M | -39.1% |
| FY2021 | Dec 31, 2021 | $70.90M | +367.3% |
| FY2020 | Dec 31, 2020 | $15.17M | +41.3% |
| FY2019 | Dec 31, 2019 | $10.74M | +50.5% |
| FY2018 | Dec 31, 2018 | $7.13M | -7.5% |
| FY2017 | Dec 31, 2017 | $7.71M | +54.1% |
| FY2016 | Dec 31, 2016 | $5.01M | +17782.1% |
| FY2015 | Dec 31, 2015 | $28.00K | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $7.29M | +8.7% |
| Q2 FY2026 | Jun 30, 2026 | $7.26M | -3.9% |
| Q1 FY2026 | Mar 31, 2026 | $10.32M | +33.7% |
| Q4 FY2025 | Dec 31, 2025 | $8.88M | +107.5% |
| Q3 FY2025 | Sep 30, 2025 | $6.70M | -28.7% |
| Q2 FY2025 | Jun 30, 2025 | $7.56M | -30.3% |
| Q1 FY2025 | Mar 31, 2025 | $7.72M | -54.1% |
| Q4 FY2024 | Dec 31, 2024 | $4.28M | -81.8% |
| Q3 FY2024 | Sep 30, 2024 | $9.41M | -61.7% |
| Q2 FY2024 | Jun 30, 2024 | $10.85M | -66.3% |
| Q1 FY2024 | Mar 31, 2024 | $16.82M | -54.9% |
| Q4 FY2023 | Dec 31, 2023 | $23.55M | -45.4% |
| Q3 FY2023 | Sep 30, 2023 | $24.58M | -51.2% |
| Q2 FY2023 | Jun 30, 2023 | $32.17M | -44.5% |
| Q1 FY2023 | Mar 31, 2023 | $37.27M | -43.6% |
| Q4 FY2022 | Dec 31, 2022 | $43.15M | -39.1% |
| Q3 FY2022 | Sep 30, 2022 | $50.39M | -33.0% |
| Q2 FY2022 | Jun 30, 2022 | $58.00M | -27.1% |
| Q1 FY2022 | Mar 31, 2022 | $66.10M | -23.4% |
| Q4 FY2021 | Dec 31, 2021 | $70.90M | +367.3% |
| Q3 FY2021 | Sep 30, 2021 | $75.18M | +487.6% |
| Q2 FY2021 | Jun 30, 2021 | $79.51M | +375.1% |
| Q1 FY2021 | Mar 31, 2021 | $86.29M | +640.8% |
| Q4 FY2020 | Dec 31, 2020 | $15.17M | +41.3% |
| Q3 FY2020 | Sep 30, 2020 | $12.80M | -17.0% |
| Q2 FY2020 | Jun 30, 2020 | $16.73M | -10.5% |
| Q1 FY2020 | Mar 31, 2020 | $11.65M | +32.6% |
| Q4 FY2019 | Dec 31, 2019 | $10.74M | +50.5% |
| Q3 FY2019 | Sep 30, 2019 | $15.41M | +79.2% |
| Q2 FY2019 | Jun 30, 2019 | $18.70M | +59.5% |
| Q1 FY2019 | Mar 31, 2019 | $8.78M | -33.0% |
| Q4 FY2018 | Dec 31, 2018 | $7.13M | -7.5% |
| Q3 FY2018 | Sep 30, 2018 | $8.60M | -1.6% |
| Q2 FY2018 | Jun 30, 2018 | $11.72M | +26.4% |
| Q1 FY2018 | Mar 31, 2018 | $13.11M | +161.9% |
| Q4 FY2017 | Dec 31, 2017 | $7.71M | +24.7% |
| Q3 FY2017 | Sep 30, 2017 | $8.74M | – |
| Q2 FY2017 | Jun 30, 2017 | $9.27M | – |
| Q4 FY2016 | Dec 31, 2016 | $5.01M | – |
| Q3 FY2016 | Sep 30, 2016 | $6.18M | – |
See a number that looks wrong?